Hyderabad-headquartered API manufacturer with global leadership in key APIs across 14 therapeutic segments.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 |
| Reserves | 340 | 402 | 462 | 452 | 528 | 631 | 751 | 776 |
| Borrowings | 157 | 255 | 263 | 254 | 281 | 311 | 324 | 365 |
| Other Liabilities | 103 | 147 | 126 | 165 | 217 | 202 | 221 | 212 |
| Total Liabilities | 608 | 812 | 860 | 880 | 1.0k | 1.2k | 1.3k | 1.4k |
| AssetsFixed Assets | 280 | 457 | 438 | 412 | 437 | 533 | 517 | 534 |
| CWIP | 42 | 7 | 11 | 33 | 30 | 35 | 50 | 122 |
| Investments | 26 | 27 | 22 | 11 | 11 | 12 | 48 | 26 |
| Other Assets | 259 | 321 | 389 | 424 | 556 | 573 | 690 | 681 |
| Total Assets | 608 | 812 | 860 | 880 | 1.0k | 1.2k | 1.3k | 1.4k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 50 | 40 | 90 | 45 | 22 | 50 | 82 | 59 |
| Cash from Investing | -35 | -43 | -152 | -27 | -30 | -52 | -123 | -131 |
| Cash from Financing | -13 | -2 | 92 | -12 | -32 | 31 | 47 | 76 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 15 | -3 | -61 | 18 | -7 | -2 | -42 | -71 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (32.7×) and current (35.4×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 265.9% growth and a 33× exit, ₹379 only delivers your return if you pay ₹2,17,339. The price is currently baking in 19% growth.
EPS grows 265.9%/yr for 5 years, then fades to 6% over 2, exits at 33×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 265.9% | 39.08 |
| FY28 | 265.9% | 142.99 |
| FY29 | 265.9% | 523.19 |
| FY30 | 265.9% | 1914.35 |
| FY31 | 265.9% | 7004.60 |
| FY32 | 135.9% ·fade | 16527.35 |
| FY33 | 6.0% ·fade | 17518.99 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.